AzTrials
AzTrials

Tuberculous MeningitisNCT05636254

Diagnostic Accuracy of Imaging Findings in TBM/Spinal Tubercular Arachnoiditis and Correlation With Outcomes

An observational study of Tuberculous Meningitis and Tuberculous Arachnoiditis, run by All India Institute of Medical Sciences at 1 site in India.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this Diagnostic accuracy study is To study sensitivity and specificity of sulcal tuberculomas in the diagnosis of tubercular meningitis and To study the correlation of imaging findings in tubercular meningitis and spinal tubercular arachnoiditis with clinical outcomes after completion of therapy Secondary… Read more about this study

Who is it for?
Ages 14 years and older
What is being tested?
MRI Brain and spine and Reference standard diagnostic criteria
How many people
120 participants
Where
1 siteIndia
Study dates
27 Jan 2022to Feb 2024
How long will I take part?
18 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 14 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: ▪ Chronic meningitis : Case definition * Headache with or without fever, nuchal stiffness and systemic symptoms AND * CSF suggestive of meningitis Pleocytosis (>20 cells per μL) with lymphocyte predominance (>50%) OR Protein concentration less greater than age-specific normal value; especially >1•0 g/L OR Glucose concentration than 60% of concentration in blood OR MRI suggestive of meningeal enhancement on contrast enhanced T1 sequences AND * Deemed by the treating physician that the syndrome is consistent with chronic meningitis

Who may be able to join

None listed.

Who cannot join

  • Not willing to provide consent

Trial locations and contacts

1 site in 1 country.

Arunmozhimaran Elavarasi, MD DM contact

+919013844274

arun_ela@yahoo.com

MV Padma Srivastava, MD DM contact

+919868398261

vasanthapadma123@gmail.com

India1 site, 1 recruiting
  • All India Institute of Medical Sciences, New Delhi

    New Delhi, National Capital Territory of Delhi, 110029

    Arunmozhimaran Elavarasi, MD DM, +919013844274, arun_ela@yahoo.com

    Padma Srivastava MV, MD DM, +919868398261, vasanthapadma123@gmail.com

    Recruiting

Other trials in India

About this study

Official title: Diagnostic Accuracy of Imaging Findings in Tubercular Meningitis/Spinal Tubercular Arachnoiditis and Correlation With Outcomes in Patients With Tubercular Meningitis, Spinal Tubercular Arachnoiditis

The goal of this Diagnostic accuracy study is

  • To study sensitivity and specificity of sulcal tuberculomas in the diagnosis of tubercular meningitis and
  • To study the correlation of imaging findings in tubercular meningitis and spinal tubercular arachnoiditis with clinical outcomes after completion of therapy
  • Secondary objectives
  • To study the proportion of patients having clinical or imaging features of spinal tubercular arachnoiditis
  • To study the factors determining outcomes in patients with spinal tubercular arachnoiditis
  • To study the treatment trends in patients with spinal tubercular arachnoiditis
Read more

The investigators will include [study Population] Patients with chronic meningitis as per criteria listed below

  • Chronic meningitis : Case definition
  • Headache with or without fever, nuchal stiffness and systemic symptoms AND
  • CSF suggestive of meningitis Pleocytosis (>20 cells per μL) with lymphocyte predominance (>50%) OR Protein concentration greater than age-specific normal value; especially >1•0 g/L OR Glucose concentration less than 60% of concentration in blood OR MRI suggestive of meningeal enhancement on contrast enhanced T1 sequences AND
  • Deemed by the treating physician that the syndrome is consistent with chronic meningitis
  • Patients who are positive for antibodies to HIV and pregnant females will also be included.
  • Willing to undergo periodic assessment clinically and with MRI as per clinical condition demands.

The sensitivity and specificity of the finding of sulcal tuberculomas will be compared to the reference standard diagnostic criteria for the diagnosis of TB meningitis.

Read the detailed description

Methodology of the study Study design:Ambispective cohort study; Observational study; Diagnostic accuracy study

Sample size: All consecutive patients in the database will be included in the retrospective study and all new patients registered in the neurology OPD and admitted in the Neurology or General Medicine or Geriatric medicine or Medical oncology wards will be included in the prospective arm

Expecting a sensitivity of 70% of sulcal tuberculomas in tubercular meningitis with a range of 60 to 80, the investigators expect (4*70*30) /10*10=84 patients Expecting sulcal tuberculomas to have a specificity of 80%, with a range of 70 to 90%, the investigators expect (4*80*20)/10*10=64 patients Expecting a 70% prevalence of tubercular meningitis amongst patients with chronic meningitis, sample size of atleast 120 patients (70% of 120=84).

Subjects:

  • Study Population: Patients with chronic meningitis as per criteria described
  • Inclusion criteria
  • Patients attending Neurology OPD or are admitted in General Medicine or Geriatric medicine or Medical oncology wards with chronic meningitis diagnosed on the basis of composite clinical criteria, imaging criteria as well as natural history of the illness
  • Atleast 14 years of age of all sexes
  • Chronic meningitis : Case definition above
  • Willing to undergo periodic assessment clinically and with MRI as per clinical condition demands.
  • Diagnostic criteria for Tuberculous meningitis ▪ Described in the diagnostic test section ahead
  • Diagnostic criteria for clinical spinal tubercular arachnoiditis ▪ Developed paraparesis/quadriparesis/sphincter dysfunction due to spinal radiculomyelitis OR areflexia OR hyperreflexia with no obvious brain parenchymal lesions (suggestive of spinal meningitis-myelitis) or vision loss due to optico-chiasmatic arachnoiditis with imaging evidence of arachnoiditis
  • Sample Size: All consecutive patients presenting with chronic meningitis as described above will be included

Exclusion criteria for prospective arm

● Not willing to provide consent

Conduct of the study

  • Study protocol
  • Consent: Participants or their legally authorized representatives will be explained about the study and informed written consent will be taken in the language they understand for the prospective study
  • Participants will undergo magnetic resonance imaging of the brain and spine with contrast using the standardized protocol for chronic meningitis used at AIIMS as the standard of care in the workup of chronic meningitis.
  • The final diagnosis of Tubercular meningitis will be made based on the criteria described above and the sensitivity and specificity of sulcal tuberculomas in the diagnosis of TBM will be determined
  • Other imaging findings of spinal tubercular arachnoiditis will be collected on a structured proforma by the radiologist who will be blinded to the clinical information on the presence or absence of clinical features.
  • Participants will follow treatment for tuberculosis as per the treating physician's discretion in terms of anti-tubercular therapy, anti-seizure medication therapy, duration and dose of corticosteroids and steroid sparing agents.
  • Data collection and analysis will be done as per protocol Follow up and outcomes assessed > Participants of the prospective arm will be carefully assessed with detailed history, clinical examination, necessary laboratory investigations and imaging > Detailed history and clinical and neurologic examination, lab parameters and imaging data will be documented into a database as per protocol > Participants will follow treatment for his/her primary condition as per the treating physician's discretion > Outcomes will be assessed at 3 months, 6 months and at end of therapy > The outcome parameters of interest will be modified Rankin scale, visual acuity at 3 months and end of therapy.

Diagnostic accuracy of imaging parameters in the diagnosis of tubercular meningitis will be assessed by sensitivity and specificity.

The investigators aim to do a descriptive study of the clinical, laboratory and imaging parameters of patients tubercular meningitis and spinal tubercular arachnoiditis and compare with patients with other forms of chronic meningitis.

The treatment strategy, usage of anti-tubercular therapy, usage of corticosteroids, steroid sparing therapy, and surgical interventions offered will be studied.

Outcomes will be assessed and compared those who have sulcal tuberculumas and those who don't. The patients with and without spinal arachnoiditis on imaging also will be compared, and their outcomes assessed. Factors affecting outcomes will be studied and exploratory analysis will be done. Statistical analysis will be performed on the available information. Qualitative data will be presented as the number and the percentage of patients in each treatment group. Quantitative data will be presented as mean and standard deviation, range, median and inter-quartile range by treatment group. The absence of imbalance between groups will be checked on baseline variables. Comparisons of qualitative variables between groups will be performed by a Fisher exact test; comparison of quantitative data will be performed by a t test or a comparison of median when they will not follow a Normal distribution. All statistical tests will be performed with the use of a two-sided type I error rate of 5%.

Being tested
MRI Brain and spine, Reference standard diagnostic criteria
Keywords
TBM
Medical subject headings
Tuberculosis, Meningeal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MRI Brain and spineDiagnostic test

    • MRI Brain
    • Ax T2 TSE
    • 3D Sag T1
    • Ax DWI
    • 3D Sag Flair
    • Ax SWI
    • Post-gad 3D Sag T1
    • 3D TOF Circle-of-Willis
    • MRI Spine
    • Sag T2 whole spine (2 stations)
    • Post-gad Sag T1 whole spine (2 stations)
  • Reference standard diagnostic criteriaDiagnostic test

    Also called Clinical composite criteria

    Diagnostic criteria-TBM

    • Microbiologic evidence of TB in CSF
    • Microbiologic evidence of TB from pulmonary or extrapulmonary sites
    • Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication suggestive of tuberculosis
    • Other relevant investigations like CSF analysis not suggestive of alternative diagnosis such as neurocysticercosis/cryptococcal/other fungal infections/other causes of chronic meningitis such as brucella/ nocardia/ syphilis/recurrent viral meningitis/ carcinomatous/ lymphomatous meningitis or non infective causes such as sarcoidoisis/sub-arachnoid hemorrhage etc.
    • Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication ruling out competing diagnoses
    • Patients who develop features or test results suggestive of alternative diagnosis with will be considered to be not due to tubercular meningitis
Study groups in NCT05636254
Study groupRoleWhat they receive
Chronic Meningitis* Chronic meningitis : Case definition * Headache with or without fever, nuchal stiffness and systemic symptoms AND * CSF suggestive of meningitis Pleocytosis (>20 cells per μL) with lymphocyte predominance (>50%) OR Protein concentration greater than age-specific normal value; especially >1•0 g/L OR Glucose concentration less than 60% of concentration in blood OR MRI suggestive of meningeal enhancement on contrast enhanced T1 sequences AND * Deemed by the treating physician that the syndrome is consistent with chronic meningitis * Patients who are positive for antibodies to HIV and pregnant females will also be included.
Receives: Diagnostic Test: MRI Brain and spine; Diagnostic Test: Reference standard diagnostic criteria

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sensitivity and specificity of sulcal tuberculomas in the diagnosis of tubercular meningitis

    Sensitivity and specificity of sulcal tuberculomas compared with reference standard clinical composite criteria

    Measured: Day 1 of diagnosis or imaging acquisition

  2. Correlation of imaging findings with clinical outcomes

    Correlation of imaging findings in tubercular meningitis and spinal tubercular arachnoiditis with clinical outcomes after completion of therapy The outcome parameters of interest will be modified Rankin scale, visual acuity at 3 months and end of therapy.

    Measured: 6 months to 18 months, average 9 months after starting treatment

Secondary outcomes (3)
  1. Clinical or imaging features of spinal tubercular arachnoiditis

    Proportion of patients having clinical or imaging features of spinal tubercular arachnoiditis

    Measured: Day 1 of diagnosis or imaging acquisition

  2. Factors determining outcomes in patients with spinal tubercular arachnoiditis

    Factors determining outcomes in patients with spinal tubercular arachnoiditis

    Measured: 6 months to 18 months, average 9 months after starting treatment

  3. Treatment trends in patients with spinal tubercular arachnoiditis

    Treatment trends in patients with spinal tubercular arachnoiditis

    Measured: 6 months to 18 months, average 9 months after starting treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Dec 2022
  2. Study start27 Jan 2022
  3. Primary completionJan 2024 (estimated)
  4. Study completionFeb 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
120 participants (estimated)
Target duration
18 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT05636254
Sponsor's protocol ID
IECPG-36/27.01.2022
Status last verified
Nov 2022
First submitted
16 Nov 2022
Last updated
5 Dec 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: To be routed through proper channel through the ethics committee

Questions about this trial

What is this clinical trial studying?

An observational study of Tuberculous Meningitis and Tuberculous Arachnoiditis, run by All India Institute of Medical Sciences at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 5 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Arunmozhimaran Elavarasi, MD DM (+919013844274, arun_ela@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sensitivity and specificity of sulcal tuberculomas in the diagnosis of tubercular meningitis (time frame: Day 1 of diagnosis or imaging acquisition). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2022; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in